NEW

MTMI Global Offers Pathways to Leadership

Medical Technology Management Institute (MTMI Global) President Ernesto A. Cerdena, PhD, MSRT (R)(CT)(CV), CRA, FAHRA, FACHE, is excited about the organization’s new Pathways to Leadership program. “We are launching our Pathways to Leadership programs to address the...

Shimadzu SONIALVISION G4 installed at Kansas Facility

Shimadzu Medical Systems USA announces the latest SONIALVISION G4 installation at Hutchinson Regional Medical Center in Hutchinson, Kansas. Hutchinson Regional Medical Center has acquired the SONIALVISION G4 R/F table system with Shimadzu’s Breakthrough Technologies....

Fujifilm Sonosite, Emergency Medicine Foundation Partner in Battle Against COVID-19

FUJIFILM Sonosite, Inc. and the Emergency Medicine Foundation (EMF), a 501(c)(3) nonprofit organization founded by the American College of Emergency Physicians (ACEP), have announced its partnership on the EMF COVID-19 Research Grant program. To support this program,...

ASE Elects New President

Judy W. Hung, MD, FASE, is the new president of the American Society of Echocardiography (ASE). She has served on the Board of Directors as Vice President and President-Elect prior to ascending to her one-year presidency. Dr. Hung will share her vision for the future...

FDA Approves Cerianna

PETNET Solutions Inc., a Siemens Healthineers company, and Zionexa USA, a wholly owned subsidiary of Zionexa SAS, have announced that the Food and Drug Administration (FDA) has approved Cerianna (fluoroestradiol F 18) injection for intravenous use. Cerianna (fluoroestradiol F 18) is a molecular imaging agent indicated for use in positron emission tomography (PET) imaging for the detection of estrogen receptor-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. Cerianna (fluoroestradiol F 18) is the first FDA-approved F-18 PET imaging agent specifically indicated for use in patients with recurrent or metastatic breast cancer.

Cerianna (fluoroestradiol F 18) will be commercially available beginning in late 2020/early 2021 through PETNET Solutions, Inc., Zionexa USA’s manufacturer and exclusive commercial distributor in the U.S. Additional manufacturing sites will be added as each site receives regulatory approval to commence manufacturing.

“PETNET Solutions Inc., is proud to work with Zionexa USA as the exclusive U.S. commercial supplier making Cerianna (fluoroestradiol F 18) accessible to imaging centers and their breast cancer patients,” said Barry Scott, Head of PETNET Solutions Inc. “Our extensive network of radiopharmacies enables us to increase access to cutting-edge radiotracers such as Cerianna (fluoroestradiol F 18), helping health care facilities address the challenge of recurrent and metastatic breast cancer.”

“Zionexa is pleased to be able to make Cerianna (fluoroestradiol F 18) commercially available through the extensive manufacturing network of PETNET Solutions Inc.,” said Peter Webner, chief executive officer of Zionexa USA. “PETNET has been a great partner to Zionexa and has surpassed our expectations as a contract manufacturer. Cerianna (fluoroestradiol F 18) will provide clinicians with additional, previously unavailable data on the estrogen receptor status of tumors across the patient’s entire body, providing additional data to enhance therapeutic decision-making.”

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *